Kiora Pharmaceuticals names Keith Lane as EVP of Clinical Development and Regulatory Affairs

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced on September 8, 2026 that it had appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective as of that date.¹

Lane joins Kiora after most recently serving as Chief Scientific Officer of Ora, Inc., an ophthalmology-focused clinical research organization, where he held that role from September 2025 to July 2026.¹ Before that, he was Senior Vice President and Therapeutic Area Head-Posterior Segment at Ora from October 2019 to September 2025, having joined the company in various roles since August 2003.¹

Over his career, Lane's work at Ora involved managing clinical and regulatory work across a large slate of eye disease studies, including a dozen large late-stage international trials that backed several U.S. drug applications, spanning multiple treatment modalities and a range of eye conditions from retinal disease to glaucoma, as the company described in its release during his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission, with experience spanning small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.¹

Under the terms of his Offer Letter, dated June 22, 2026, Lane will receive an annual base salary of $350,000, a sign-on bonus of $75,000, and is eligible for a performance bonus targeted at up to 35% of his base salary.¹ The company also plans to grant him an option to purchase up to 55,000 shares of common stock, subject to approval by the Compensation Committee and issuance under the 2024 Equity Incentive Plan.¹ That option will vest one-third after one year, with the remainder vesting monthly over the following two years.¹

Kiora said Lane's duties will include work on the company's clinical and registration programs, including support for KIO-301 in retinitis pigmentosa and related inherited retinal diseases in coordination with partners, according to CEO Brian Strem.